Spotlight on cerebrolysin in dementia

CNS Drugs

Volumn 24, Issue 3, 2010, Pages 263-266

  Plosker, Greg L ^a   Gauthier, Serge ^b  

^a Wolters Kluwer Business ^*  (New Zealand)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROLYSIN; DONEPEZIL; NEUROTROPHIC FACTOR; PLACEBO;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTHRALGIA; CLINICAL TRIAL; COGNITION; DELUSION; DEMENTIA; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DYSTHYMIA; HUMAN; HYPOKINESIA; INSOMNIA; MULTIINFARCT DEMENTIA; MUSCLE SPASM; NAUSEA; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SWEATING; TREATMENT DURATION; URINARY TRACT INFECTION; VERTIGO;

AMINO ACIDS; DEMENTIA; HUMANS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 76949085182     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11204820-000000000-00000     Document Type: Short Survey

References (35)

1. Hartbauer M, Hutter-Paier B, Skofitsch G, et al. Anti-apoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm 2001; 108 (4): 459-473
2. Akai F, Hiruma S, Sato T, et al. Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 1992 Apr; 7 (2): 213-221
3. Alvarez XA, Lombardi VRM, Fernandez-Novoa L, et al. Cerebrolysin® reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J Neural Transm Suppl 2000; 59: 281-292
4. Veinbergs I, Mante M, Mallory M, et al. Neurotrophic effects of Cerebrolysin® in animal models of excitotoxicity. J Neural Transm 2000; 59 Suppl.: 273-280
5. Ubhi K, Rockenstein E, Doppler E, et al. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathol 2009 Jun; 117 (6): 699-712
6. Rockenstein E, Torrance M, Mante M, et al. Cerebrolysin decreases amyloid-P production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res 2006 May 15; 83 (7): 1252-1261
7. Rockenstein E, Adame A, Mante M, et al. The neuroprotective effects of Cerebrolysin™ in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 2003 Nov; 110 (11): 1313-1327
8. Rockenstein E, Mallory M, Mante M, et al. Effects of Cerebro-lysin™ on amyloid-|3 deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl 2002; 62: 327-336
9. Rockenstein E, Mante M, Adame A, et al. Effects of Cerebro-lysin™ on neurogenesis in an APP transgenic model of Alzheimer's disease. Acta Neuropathol 2007 Mar; 113 (3): 265-275
10. Tatebayashi Y, Lee MH, Li L, et al. The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathol 2003 Mar; 105 (3): 225-232
11. Chen H, Tung YC, Li B, et al. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 2007 Aug; 28 (8): 1148-1162
12. Masliah E, Armasolo F, Veinbergs I, et al. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 1999 Feb; 62 (2): 239-245
13. Gschanes A, Windisch M. The influence of Cerebrolysin® and E021 on spatial navigation of 24-month-old rats. J Neural Transm 1998; 53 Suppl.: 313-321
14. Valouskova V, Francis-Turmer L. The short-term influence of b-FGF, NGF and Cerebrolysin® on the memory impaired after fimbria-fornix lesion [abstract]. J Neural Transm Suppl1996; 47: 280 (Pubitemid 26275611)
15. Francis-Turner L, Valouskova V, Mokry J. The long-term effect of NGF, b-FGF and Cerebrolysin® on the spatial memory after fimbria-fornix lesion in rats [abstract]. J Neural Transm Suppl 1996; 47: 277 (Pubitemid 26275608)
16. Valouskova V, Gschanes A. Effects of NGF, b-FGF, and cerebrolysin on water maze performance and on motor activity of rats: short-and long-term study. Neurobiol Learn Mem 1999 Mar; 71 (2): 132-149
17. Frey II WH, Hanson LR, Liu X-F, et al. Quantitative and qualitative distribution of 125I-labeled Cerebrolysin peptides in the CNS following IN delivery. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2005 Jun. (Data on file)
18. Gschanes A, Valouskova V, Windisch M. Ameliorative in-fluence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion. J Neural Transm 1997; 104 (11-12): 1319-1327
19. Alvarez XA, Cacabelos R, Sanpedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2009. (Data on file)
20. Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006 Jan; 13 (1): 43-54
21. Bae C-Y, Cho C-Y, Cho K, et al. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. J Am Geriatr Soc 2000 Dec; 48 (12): 1566-1571
22. Panisset M, Gauthier S, Moessler H, et al. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 2002 Jul; 109 (7-8): 1089-1104
23. Ruether E, Husmann R, Kinzler E, et al. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol 2001 Sep; 16 (5): 253-263
24. Ruether E, Alvarez XA, Rainer M, et al. Sustained improve-ment of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin®. J Neural Transm 2002; 62 Suppl.: 265-275
25. Alvarez A, Cacabelos R, Aleixandre M, et al. Synergistic treat-ment effects with Cerebrolysin and donepezil: results from a randomized, double-blind, multicenter trial to compare safety and effiacy of Cerebrolysin, donepezil and a combination of both in patients with probable Alzheimer's disease [abstract]. International Conference on Alzheimer's Disease; 2009 Jul 11-16; Vienna
26. Alvarez XA, Cacabelos R. Integrated clinical study report (protocol EBE031010): a randomized, double-blind, clinical trial to compare the safety and efficacy of a Cerebrolysin and Aricept (donepezil) and a combination therapy in patients with probable Alzheimer's disease. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2008 Nov 27. (Data on file)
27. Xiao S, Yan H, Yao P, et al. Efficacy of FPF 1070 (Cere-brolysin) in patients with Alzheimer's disease: a multicentre, randomised, double-blind, placebo-controlled trial. Clin Drug Invest 2000 Jan; 19 (1): 43-53
28. Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin®. J Neural Transm 2002; 62 Suppl.: 277-285
29. Ruther E, Ritter R, Apecechea M, et al. Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 1994 Jan; 27 (1): 32-40
30. Guekht A, Moessler H, Doppler E, et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial [abstract plus poster]. 9th International Conference for Alzheimer's and Parkinson's Disease; 2009 Mar 11-15; Prague
31. Gusev EI. Integrated clinical study report (protocol EBE-RU-051201). A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with vascular dementia. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2008 Aug 18. (Data on file)
32. Muresanu DF. The influence of Cerebrolysin on cognitive performances in patients suffering from vascular dementia. Unterach, Austria: EBEWE Pharmaceuticals Ltd, 1999
33. Muresanu DF, Alvarez XA, Moessler H, et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. J Neurol Sci 2008 Apr 15; 267 (1-2): 112-119
34. Vereschagin NV, Nekrasova EM, Lebedova NV, et al. Mild forms of multi-infarct dementia: effectiveness of cerebrolysin [in Russian]. Sov Med 1991; (11): 6-8
35. Rainer M, Brunnbauer M, Dunky A, et al. Therapeutic re-sults with Cerebrolysin® in the treatment of dementia. Wien Med Wochenschr 1997; 147 (18): 426-431